Twist Bioscience Corporation (NASDAQ:TWST) on Monday posted first-quarter 2026 results of a loss of 50 cents per share, in line with Wall Street expectations.
Revenue reached $103.70 million, up 17% year over year, exceeding consensus of $102.72 million and management guidance of $100 million to $101 million.
Adjusted EBITDA loss for the quarter was $13.4 million, compared to a loss of $16.3 million a year ago.
The company shipped products to about 2,538 customers in the first quarter of 2026, compared to about 2,376 a year ago.
Gross margin for the first quarter of fiscal 2026 increased to 52%, compared to 48.3% a year ago.
As of December 31, 2025, the Company had approximately $198 million in cash, cash equivalents and short-term investments.
“As we move forward this year and beyond, we remain focused on pursuing profitability with consistent revenue growth, gross margins above 50% and disciplined spending to invest in scalable, sustainable growth opportunities, while serving more customers, launching more products and expanding our addressable markets,” said Emily LeperCEO and co-founder of Twist Bioscience.
Outlook
Twist Bioscience raised fiscal 2026 sales guidance from $425 million – $435 million to $435 million – $440 million, compared to the consensus of $431.39 million.
The guidance expects that sales growth versus previous guidance will be generally balanced across DSPS and NGS.
The gross margin is expected to exceed 52% for the 2026 financial year.
Twist reiterates its expectation to achieve adjusted EBITDA breakeven for the fourth quarter of fiscal 2026.
The company expects second-quarter 2026 revenue between $107 and $108 million, compared to the consensus of $105.84 million.
Analyst Take
William Blair wrote: “We remain confident in the company’s long-term revenue growth trajectory as it invests aggressively to penetrate multiple distinct markets, collectively giving the company a long runway of 20%+ growth and a variety of upside opportunities on target.”
Analyst Matt Larew sees the company’s efforts as moderate investments as it scales up to FOTF and aims to break even on adjusted EBITDA. This makes sense and should increase the story’s appeal if the company can achieve that goal.
William Blair rates the stock as Outperform.
TWST price promotion: Shares of Twist Bioscience were up 10.59% to $45.42 at the time of publication on Monday, according to data from Benzinga Pro.
Photo by jittawit21 via Shutterstock
#Twist #Bioscience #stock #rising #Monday #Twist #Bioscience #NASDAQTWST